Aktuella utlysningar, vecka 5, 2024
KI Grants Office tipsar om aktuella utlysningar
Svenska och nordiska utlysningar
Forskningsanslag - Stiftelsen Kempe-Carlgrenska fonden
Stiftelsen välkomnar ansökningar från doktorander/post doc/forskare vars arbete är på hög vetenskaplig nivå och gällande barn eller ungdoms psykosociala situation och skolgång. Stiftelsen delar i första hand ut skattefria stipendier till doktorander (18 000 kr/månad) och post-doc (25 000 kr/månad). Ibland beviljas forskningsanslag. Projektledaren ska i så fall dokumentera sina meriter genom ett vidimerat cv och institutionens administrative chef/motsvarande, intyga att projektet bedrivs vid den aktuella institutionen.
Closing date: February 28, 2024
Travel grants - Radiumhemmets Forskningsfonder
Support research associated participation in courses and congresses within clinical cancer research. Grants normally cover return tickets partly or in full to the lowest ticket cost, hotel costs, registration fee and transfer to and from the airport.
Closing date: March 1, 2024
Forskningsanslag - Stiftelsen Läkare Mot AIDS FORSKNINGSFOND
Stiftelsen stöder forskning kring HIV-infektion och AIDS, särskilt aspekter avseende behandling, prevention och vaccin. Prioritet ges till projekt som har klinisk anknytning och till sökande som nyligen påbörjat sin forskning. Maximalt anslag: 400 000 kr
Closing date: March 1, 2024
Projektbidrag och kliniska forskarmånader - Centrum för Innovativ Medicin (CIMED)
CIMED utlyser projektmedel för kliniska forskningsprojekt och forskarmånader för kliniskt verksamma forskare för 2025-2027. Bidragen kan sökas i samma ansökan. Medel söks av enskild kliniskt inriktad junior eller senior forskare med sin verksamhet knuten till en av institutionerna på Karolinska Institutet vid Campus Flemingsberg. Forskningsprojektet ska helt vara förlagt till Campus Flemingsberg, med 1-2 medsökande per projekt. Bidragstid för projektbidrag är 1 till 3 år med 0,3 till 1,0 MSEK/år. Bidragsbelopp för kliniska forskarmånader (1-3 månader) är 130 000 kr/månad.
Closing date: March 3, 2024.
Forskningsanslag - ÅForsk stiftelsen
Stödjer forskning och utveckling inom energi, miljö, hållbarhet, utveckling av processer, infrastruktur, material, produkter från förnybara källor och säkerhet. Tre typer av anslag kan sökas: i) ung forskare , max fem år från disputation. Anslaget gäller för endast ett år, maxbelopp är 500 000 kr inkl totalt max 30% omkostnadspåslag (OH). ii) Samverkansprojekt mellan akademi/industri, medfinansiering från antingen universitet/högskolor eller företag är en bonus. Anslaget kan sökas för max tre år. iii) Generell forskning, anslag kan sökas för max tre år.
Closing date: March 10, 2024. Application period opens February 6, 2024.
Forskningsstipendier - Riksföreningen för anestesi och intensivvård (Rf AnIva)
Rf AnIva strävar efter att synliggöra forskningsresultat samt att det kliniska arbetet sker ur ett evidensbaserat perspektiv. Forskningsstipendium anslås därför varje år i syfte att stödja sjuksköterskors forskningsarbete inom anestesi, intensivvård eller närliggande verksamhetsområden. Forskningsstipendiet är för närvarande på 40 000 kronor. Sökande ska vara registrerad som doktorand, bedriva forskning inom anestesi, intensivvård eller närliggande verksamhetsområden och vara medlem hos Rf AnIva.
Closing date: March 15, 2024
Forskningsprojekt – Sjöbergstiftelsen
Stiftelsen ger bidrag till cancerforskning inom forskningsområdena: (i) Förebyggande åtgärder och omvårdnad inklusive komplementär och integrativ medicin och åtgärder mot långsiktiga komplikationer; (ii) Tidig diagnostik samt svårbehandlad cancer med dålig prognos och även ”drug repurposing”. Inom ovanstående forskningsområden kan också olika forskargrupper lämna in en gemensam större ansökan (>6 000 000 kr) avseende bidrag till uppbyggnad och konsolidering av nationellt nätverk för forskning.
Closing date: March 31, 2024
Stipendier för Forskning och Vetenskap - Apotekarsocieteten
Stiftelsens ändamål är att främja vetenskapliga studier och forskning som täcker olika typer av farmaceutisk forskning från tidig läkemedelsutveckling till läkemedelsanvändning. Societeten delar årligen ut stipendier för farmaceutisk forskning, utbildning, verksamhet samt bidrag till behövande. Du kan söka stipendier för fort- och vidareutbildning, för konferenser och resor under forskarutbildning samt för postdoktorala studier utomlands efter avlagd doktorsexamen. Stipendier för resebidrag för att möjliggöra examensarbete utomlands inom läkemedelsområdet om minst 30 hp under 2024. Post doc-stipendium om max 600 000 kronor för att främja grundläggande läkemedelsforskning under ett år (heltid) vid ett välrenommerat universitet utomlands eller i Sverige efter avlagd doktorsexamen med möjlighet till förlängning ytterligare ett år. Stipendier endast kan sökas för resekostnader, ej för boende mm.
Closing date: March 31, 2024
Europeiska anslag
Research grants - Fondation Jérôme Lejeune
This program supports fundamental, translational and clinical research projects. The 2024 Spring call for FJL Grants is aiming at supporting fundamental, translational and clinical research programs related to Down syndrome and other intellectual disabilities of genetic origin with early onset such as Fragile-X syndrome, Rett syndrome, Smith-Magenis syndrome, Cri du chat syndrome, Williams-Beuren syndrome, Prader-Willi syndrome, Angelman syndrome, among others.
Autism not linked to the above diseases is excluded from this call.
Closing date: 4 March 2024
Research grants - Fondation Jérôme Lejeune
Calls for proposals – EDCTP3
The Global Health EDCTP3 JU invests in global health through funding collaborative research and innovation projects tackling infectious diseases and supporting activities for research capacity building in Africa.
Several information sessions will take place on 6 and 7 February to provide further guidance to interested parties on the 2024 Work Programme and its calls for proposals. A Frequently Asked Questions (FAQs) document will be published following these events.
Open calls:
New tools, technologies and approaches for vector control in sub-Saharan Africa - HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed, tailored towards, and contributing to the development and evaluation of tools, technologies and approaches for vector-borne diseases, including vector control and disease management technologies.
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa - HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage
Expected Outcome:
This topic aims at supporting activities that contribute to one or several of the expected impacts for this call. To that end, proposals submitted under this topic should aim for delivering results that are directed, tailored towards and contributing to at least two of the following expected outcomes:
- Evidence of efficacy, safety and clinical utility for health care professionals and clinicians in sub-Saharan Africa about novel, targeted HIV therapeutics that improve treatment outcomes and quality of life;
- Innovative HIV therapeutics that have demonstrated meaningful advances over existing therapeutic interventions for patients living with HIV in terms of their ability to improve efficacy, safety, adherence, quality of life and reduce HIV-associated mortality and morbidity.
- Public health authorities and policy makers have information from comprehensive clinical trial data on the overall health effects of novel therapeutic HIV interventions, helping them to draft updated or new evidence-based clinical guidelines and best practices as well as design tailor-made HIV policies.
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa - HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage
Expected Outcome:
This topic aims at supporting activities that contribute to at least two of the expected impacts for this call. Proposals under this topic should aim at delivering results that are contributing to the following expected outcomes:
- Accelerate development of therapeutics towards registration to make progress in the control and elimination of NTDs in sub-Saharan Africa;
- Improve the understanding of barriers for progression of existing and new therapeutics against NTDs through the R&D pipeline;
- Generate evidence-based recommendations on how to better integrate research and innovation in efficient supply chains for NTDs;
- Gain a better understanding of different country or region-specific health and research needs, to ensure a better case management of patients with NTDs;
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials - HORIZON-JU-GH-EDCTP3-2024-01-04-two-stage
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed, tailored towards, and contributing to the following expected outcomes. Proposals need to address at least two of these, with the first bullet point being compulsory:
- Improvement of the use of existing antimicrobials to reduce AMR and providing data contributing to their equitable access in sub-Saharan Africa, and/or the advancement of late-stage clinical R&D of novel antimicrobials with improved properties (efficacy, safety, resistance pattern, useability) in the clinical trials pipeline;
- Data about development and implementation of antimicrobial stewardship (AMS) processes to optimise the use of antimicrobial medicines in human health and reduce antimicrobial resistance (AMR), employing the One Health approach;
- Effective infection prevention control measures, sanitation and hygiene to reduce the need for and the use of antimicrobial medicines.
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Innovative digital health solutions for sub-Saharan Africa - HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage
ExpectedOutcome:
This topic aims at supporting activities that contribute to one or several of the expected outcomes for this call. Proposals under this topic should aim to deliver results that are contributing to the following expected outcomes:
- Development, improvement and/or scaling-up of digital innovative solutions supporting clinical research through smart, highly innovative digital health technologies or concepts to accelerate the development of preventive, therapeutic or diagnostic interventions addressing poverty-related diseases in sub-Saharan Africa;
- Development, improvement and/or scale-up of new digital technologies in public health interventions that can serve as drivers for the strengthening of health systems in sub-Saharan Africa. The proposed digital solutions should allow notably but not exclusively the improvement of development, production and access to health countermeasures, data and research evidence for better health outcomes and for the development and implementation of informed health policies and/or improved clinical guidelines in sub-Saharan Africa;
- Contribution to the implementation of national and/or overarching regional digital health strategies.
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Research on existing Malaria vaccines and development of new promising candidates - HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage
ExpectedOutcome:
This topic aims at supporting activities that are contributing to one or several of the expected impacts for this call. Proposals submitted under this topic should aim at delivering results that contribute to at least two of the following expected outcomes:
- Generating evidence required for accelerating registration of new vaccine candidates;
- Generating long-term safety and efficacy data on currently registered vaccines;
- Safety and efficacy results from other vaccines, especially those targeting all stages of plasmodium falciparum lifecycle, including promising candidates in phase 2a/b;
- Generating evidence-based recommendations on how to boost manufacturing capacity and build an efficient supply chain for vaccines in general, and malaria vaccines in particular sub-Saharan Africa.
Closing date: 1st stage 4 April 2024, 2nd stage 12 September 2024
Amerikanska anslag
Federal Funding
Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of Post-Acute Sequelae of SARS-CoV-2 Infection on Mission Specific Sensory and Communication Disorders
Funding Opportunity ID: NOT-DC-24-001
Upcoming deadlines: This notice applies to due dates on or after January 30, 2024 and subsequent receipt dates through January 30, 2027.
Abstract: Post-acute sequelae of SARS-CoV-2 (PASC), also referred to as long COVID, is defined as signs, symptoms, and conditions that continue or develop after initial COVID-19 infection. Such signs, symptoms, and conditions linger or develop 4 or more weeks following the acute infection, and can last weeks, months, and even years. Furthermore, PASC-related symptoms are wide ranging, and can have cardiopulmonary, gastrointestinal, dermatologic, endocrine, psychiatric and/or neurological manifestations, including sensory dysfunction and cognitive-communication difficulties. Further research is critical to understand the symptomatology, pathogenesis, and underlying mechanisms of PASC. NIDCD invites applications for research on PASC in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.
CDMRP - Autism Research Program (ARP) - Anticipated Funding Opportunity for Fiscal Year 2024 (FY24)
Award Mechanisms: Clinical Trial Award; Idea Development Award; Career Development Award; Discovery Award
Abstract: The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not been appropriated for the Autism Research Program (ARP), the ARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 Defense Appropriations Act is anticipated to provide funding for the ARP to support research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD). The ARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 ARP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
NIH - Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not Allowed)
Funding Opportunity ID: RFA-DA-25-034
Upcoming deadlines: 14th August, 2024
Abstract: The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing mechanistic transdisciplinary research in animal models that integrates approaches across social/cognitive neuroscience with perspectives from fields with complementary approaches to the study of social behavior, with the goal of developing a testable conceptual or computational model that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of Substance Use Disorders (SUDs) and comorbidities. This NOFO is intended to support basic or translational research in non-human animal models, including secondary analysis of data from research in animal models. Applications including studies involving human subjects should submit under one of the companion NOFOs. Applications with observational research in humans, secondary analysis of human subjects data, or research specifically aimed at studying disease processes or evaluating clinical interventions should submit under the companion Clinical Trials Optional NOFO, RFA-DA-25-032. Applications proposing Basic Experimental Studies involving Humans should be submitted under the companion “Basic Experimental Studies with Humans (BESH) Required” NOFO, RFA-DA-25-033.
NIH - Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
Funding Opportunity ID: PAR-24-111
Upcoming deadlines: Standard dates apply.
Abstract: The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.
Foundation
Brain & Behavior Research Foundation (BBRF), US – Young Investigator Grants
Upcoming deadlines: Full application –12th March, 2024
Amount: $70,000 over 2 years. Indirect costs are not covered by this grant.
Eligibility: The YI Grant is intended to support advanced post-doctoral fellows, instructors and assistant professors (or equivalent). Predoctoral students, first year post-doctoral fellows, faculty who serve(d) as a principal investigator (PI) on a NIH R01 grant are not eligible. Investigators at the rank of associate professor or equivalent are also not eligible (assistant professors who serve(d) as a principal investigator (PI) on a NIH R01 or equivalent grant are now eligible for the BBRF Independent Investigator Grant). Applicants must have an on-site mentor or senior collaborator who is an established investigator in areas relevant to psychiatric disorders. Applicants may only apply twice for an initial BBRF Young Investigator Grant.
Abstract: The program is intended to facilitate innovative research opportunities and supports basic, as well as translational and/or clinical investigators. All research must be relevant to our understanding, treatment and prevention of serious psychiatric disorders such as: schizophrenia; bipolar; mood and anxiety disorders or early onset brain and behavior disorders. In addition to supporting the full ranges of relevant neurobiological and psychobiological basic science, we also support clinical science, which can include careful studies using qualitative research approaches or research generating preliminary data to explore a new hypothesis generated by clinical experience or large sample studies.
Children's Tumor Foundation (CTF), US – NF Clinical Research Award
Upcoming deadlines: LOI - 12th February, 2024; Full application - 1st April, 2024
Amount: Two years funding of up to $150,000 total inclusive of 10% indirect costs. Can request up to $1,500 additional travel allowance.
Eligibility: MDs, PhDs, research fellows, and holders of MS, GC, NP, and equivalent degrees.
Abstract: The Clinical Research Award program supports early-stage pilot clinical trials of candidate therapeutics or interventions for the treatment of physical or psychosocial manifestations of NF1, SWN, or NF2-SWN. This grant mechanism also includes adjunct studies, such as the development of biomarkers, imaging protocols, and other clinical trial tools.
Alzheimer's Association (AA), US – various research grants
Upcoming deadlines: LOI – 28th February, 2024; Full application – 1st May
Amount: See link for individual program funding. Indirect costs are covered up to 10%.
Eligibility: See link for individual program eligibilities.
Abstract: Alzheimer's Association is accepting applications for 3 new funding opportunities:
Alzheimer's Association Research Grant (AARG) - The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to federal or other funding entities.
Alzheimer's Association Research Fellowship (AARF) - This award is intended to support exceptional researchers who are engaged in their post-graduate work (i.e., postdoctoral fellows) and before they have their first independent faculty positions (i.e., Assistant Professor) and working in diverse areas of research, including basic, translational, clinical, functional and social-behavioral research.
Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program - The Alzheimer's Association recognizes the need to support the training of clinician scientists in Alzheimer's and all other dementias. The areas of research that the clinician scientist proposes for funding are not limited to patient-oriented, human subject research, but may also include translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. Disease related basic science studies not directly involving humans or human tissue are also encouraged.
Lung Cancer Research Foundation (LCRF), US – various research grants
Upcoming deadlines: LOI – 4th March, 2024; Full application – 10th June
Amount: See link for individual program funding. Indirect costs are covered up to 10%.
Eligibility: See link for individual program eligibilities.
Abstract: In keeping with our mission, the LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer. Our funding mechanisms are designed to fund innovative projects across a variety of diverse topics and to support the careers of talented scientists. LCRF is accepting applications for 5 new funding opportunities:
- IASLC/LCRF Team Science Award (TSA) on Advancing Therapies Towards Curing Oncogene-Driven Lung Cancers
- LCRF Leading Edge Research Grant Program
- LCRF Minority Career Development Award (CDA) in Lung Cancer
- LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer
- LCRF Research Grants on Understanding Resistance in Lung Cancer
The Paul G. Allen Frontiers Group, US – Allen Distinguished Investigator (ADI) Program
Upcoming deadlines: LOI – 14th February, 2024; Full application – by invitation
Amount: $1,500,000 for three years. Indirect costs are not supported.
Eligibility: US or international scientists associated with eligible research organizations and pursuing independent research (e.g., faculty or similar positions) are eligible to apply. Allen Institute employees, fellows, Scientific Advisory Council (SAC) members or advisors are not eligible to apply during their tenure at the Allen Institute. Individuals, including project PIs, co-investigators, and collaborators, receiving support from the Paul G. Allen Family Foundation are not eligible to be part of applications while their award is active. We ask that, if awarded, the leader commit a minimum of 20% effort to the ADI research activities.
Abstract: The Paul G. Allen Frontiers Group is accepting applications for 2 new funding opportunities as part of its Distinguished Investigator (ADI) Program:
Organelle Communication - We seek a set of creative proposals that elucidate new perspectives on inter-organelle communication via membrane-membrane contact sites, with a focus on discovering new biological principles in these interactions. Such new perspectives on membrane contact sites include exploration of new fundamental biological functions and mechanisms of action (e.g., via metabolic compartmentalization), and functional characterization of dynamic changes in membrane contact sites in time and intracellular space (e.g., mechanisms of regulation, coordination, and integration with other cellular processes and components).
Membrane Biophysics - We seek a set of creative proposals that develop new experimental approaches for probing the biophysics of cellular membranes to explore and reveal essential aspects of the interplay between membrane form, function, and dynamics. Such approaches encompass new technologies for perturbing, analyzing, and observing cellular membranes (with priority given to non-imaging-based technologies, for example leveraging material sciences, etc.) and/or new analytical frameworks (including prioritizing integration of theory and creative uses of new or existent model systems and their combinations).